



ISSN (E): 2277- 7695
 ISSN (P): 2349-8242
 NAAS Rating: 5.03
 TPI 2019; 8(12): 304-309
 © 2019 TPI
 www.thepharmajournal.com
 Received: 08-10-2019
 Accepted: 12-11-2019

K Pansuriya
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India

P Parejiya
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India

D Suthar
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India

P Shelat
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India

A Vekariya
 Alembic Pharmaceutical
 Limited, Vadodara, Gujarat,
 India

H Patel
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India

Development and validation of RP-HPLC method for quantitative determination and estimation of asenapine maleate in bulk and buccal (effervescent) dosage form

K Pansuriya, P Parejiya, D Suthar, P Shelat, A Vekariya and H Patel

Abstract

Asenapine Maleate is a atypical antipsychotic drug. It was approved by USFDA in august 2009. It is an antagonist of 5-HT dopamine and α -adrenergic receptors and high affinity for dopamine D₂ and serotonin 5-HT_{2A} receptor. It is indicated for treatment of various psychotic conditions like schizophrenia and bipolar disorder in adults. So it leads to the requirement of accurate and precise quantification in its bulk and buccal (effervescent) dosage form. The analytical method was developed and validate as per ICH guideline. The proposed RS-HPLC method fulfill the need at 100.8% accuracy with precision of 0.25% relative standard deviation. Waters alliance HPLC system with column Inertsil ODS 3V (150mm × 4.6mm, 5 μ m) having UV-detector at 270 nm wavelength was used. Mobile phase having mixture of 550 mL Acetonitrile and 450 mL of Milli-Q water and 1mL Ortho Phosphoric Acid (OPA) was used. The flow rate was set to 1.5 mL/min that give the retention time at 4.9 min for Asenapine Maleate. The method is found linear ($r^2=0.999$ and $R=1$) for concentration range of 50 ppm to 75 ppm with zero percent interference at specificity. Robustness of the proposed method provides the back support for analysis of sample in unfavorable laboratory condition and instrumental variation. This method can be easily transferable to quality control laboratory and even at institution platform too.

Keywords: Asenapine maleate, antipsychotic, RS-HPLC, ICH-guideline

1. Introduction

The chemical name of Asenapine maleate is 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz (2, 3-6, 7) oxepino (4,5-c) pyrrole ^[1] and the structure is as shown in Fig. 1. The molecular formula of Asenapine maleate is C₁₇H₁₆ClNO.C₄H₄O₄. Molecular weight of Asenapine maleate is 401.84gm/mol². It is sparingly soluble in 0.1M HCl, soluble in methanol. Asenapine maleate is white to off white non hygroscopic powder. Asenapine Maleate is a typical antipsychotic drug. It is an antagonist of 5-HT dopamine and α -adrenergic receptors and high affinity for dopamine D₂ and serotonin 5-HT_{2A} receptor. It was approved by USFDA in august 2009 ^[3]. It is indicated for treatment of various psychotic conditions like schizophrenia and acute mania associated with bipolar disorder in adults. It also belongs to the Dibenzo-oxepino pyrrole class ^[2]. It is also for sever post-traumatic stress disorder nightmares in soldiers as an off-label use. Asenapine is a serotonin, dopamine, noradrenaline and histamine antagonist in which Asenapine possess more potent activity with serotonin receptors than dopamine ^[2].

Asenapine is a potent drug and it falls in BCS (Biological Classification system) Class-II ^[4]. Its potent nature and low solubility creates hurdles in development of formulation as well its analytical method development. Literature review reveals the estimation of Asenapine by UV-visible spectrophotometric method ^[5, 6] but compare to RS-HPLC method, that method is not more reliable. HPLC method was also found ^[7] but the proposed method is far superior in all aspects from peak shape to the validation data of method. Other method suggest estimation by Mass spectrometry method in human plasma that is again high cost analysis. The proposed method overcome all the issues with objective of simple, precise, accurate, robust and cost effective method. This method aimed to develop and validate a qualitative and quantitative method for estimation of Asenapine Maleate in bulk and Buccal dosage form by RP-HPLC method as per ICH guidelines ^[8].

Corresponding Author:

K Pansuriya
 KB Institute of Pharmaceutical
 Education and Research,
 Gandhinagar, Gujarat, India




Fig 1: Asenapine maleate

Materials and Methods

Chemicals and Reagents: Asenapine maleate was obtained from Sun Pharmaceutical Limited, Vadodara, Gujarat, India. Buccal Tablet (buccal effervescent tablet) was prepared at Vovantis Laboratory, Vadodara, Gujarat, India. Milli-Q water was used during whole study. Methanol and Acetonitrile were of HPLC grade (Make-Rankem).

Instruments and chromatographic conditions: Waters alliance and Shimadzu LC-2010HT equipped with UV-Visible detector controlled by Empower 3 software were used with column Inertsil ODS 3V (150mm × 4.6mm, 5µm), at 270 nm wavelength was used. Mobile phase having mixture of 550 mL Acetonitrile and 450mL of Milli-Q water and 1mL Ortho Phosphoric Acid (OPA) was used. All weighing were done on Sartorius analytical balance. Thermo Lab made hot air oven used in study. Ultrasonic bath of Labman was used.

Preparation of mobile phase, Standard and sample solution: An Isocratic mobile phase was prepared by mixing 550 mL Acetonitrile and 450 mL of Milli-Q water and 1mL Ortho Phosphoric Acid (OPA) and sonicated for 15 minutes to degas. The same mobile phase was used as diluent. Standard stock solution was prepared by dissolving 25mg of Asenapine Maleate in 100mL volumetric flask and standard solution (50ppm) was prepared by further diluting 5mL of this solution to 25mL with diluent. Linearity solutions (seven level) were prepared, using the standard stock solution, in the range from 25ppm (50% of standard solution) to 75ppm (150% of standard solution). To prepare sample solution weighed 20 Tablets and calculated average weight. Crushed tablet to powder and transferred tablet powder equivalent to 25mg of Asenapine Maleate in 100 mL flask. Added 70 mL diluent and sonicated for 15min and made up to mark with diluent. Then further diluted 5 mL of this solution to 25mL with diluent. Filter the resultant solution through 0.45µm

PVDF filter and was used as the sample solution. Placebo was prepared in same manner as sample with all excipients except Asenapine Maleate.

Method Validation: The RP-HPLC method was validated according to ICH Guidelines for validation of analytical procedures for different validation parameters. The method was validated for its specificity, Linearity, accuracy, precision, ruggedness, robustness, LOD and LOQ.

Result and Discussion

System suitability and system precision: To ascertain its effectiveness 10µL of freshly prepared standard solution was injected six times. System suitability and system precision data were calculated. The results obtained are shown in Table 1-2.

Table 1: Summary of system suitability criteria in standard solution

Sr. No.	Parameter	Observation (Limit)
1	The % RSD of Asenapine Maleate peaks for six replicate injections of standard.	0.01 ($\leq 2\%$)
2	The number of Theoretical Plates for Asenapine Maleate peak in standard solution	7227 (> 2000)
3	The Tailing Factor for Asenapine Maleate peak in standard solution	1.04 (< 2.0)

Table 2: Summary of peak area for system precision

Injection no.	Peak area (Asenapine Maleate)
1	2007124
2	2006678
3	2007174
4	2006560
5	2006720
Average peak area	2006851
SD	278.7
%RSD	0.01

Solution stability: Solution stability was performed by analyzing standard and sample preparation periodically in to HPLC system at sample cooler temperature and Room temperature. The obtained data were summarized in Table-3 and Table-4. The data shows that the standard solution was stable up to about 48 hours at sample cooler temperature (20 °C) and about 31 hours at Room temperature. Sample solution was stable up to about 49 hours at sample cooler temperature (20 °C) and 39 hours at room temperature.

Table 3: Stability of Standard and Test Solution at Test Method Temperature (20 °C):

Time (hours)	Standard		Time (hours)	Test	
	Area response	Cumulative % RSD		Area response	Cumulative % RSD
Initial	2006901	NA	Initial	1878356	NA
5	2009683	0.10	5	1896579	0.68
13	2016992	0.26	13	1904731	0.71
23	2008418	0.22	22	1886243	0.61
31	2011105	0.19	30	1898742	0.56
39	2020234	0.26	39	1914223	0.68
48	2030865	0.42	48	1922525	0.80

Table 4: Stability of standard and test solution at room temperature

Time (hours)	Standard		Time (hours)	Test	
	Area response	Cumulative % RSD		Area response	Cumulative % RSD
Initial	2006901	NA	Initial	1878356	NA
6	2014583	0.27	5	1893274	0.56
14	2009782	0.19	14	1909025	0.81
23	2023013	0.35	23	1912109	0.82
31	2028206	0.44	31	1916251	0.83
39	2122724	2.17	39	1897995	0.74
49	2032559	1.98	49	1998441	2.03

Specificity: A study to establish the interference of blank and placebo was conducted. The analysis was performed on placebo preparation and diluent as blank. As shown in Fig. 2-

5, it clearly indicate the ability of the method in the presence of other excipients.




Fig 2: Chromatogram of Blank




Fig 3: Chromatogram of Placebo




Fig 4: Overlay graph of Blank and standard




Fig 5: Overlay graph of placebo and sample

Linearity and Range: Inject each level into the chromatographic system and measure the peak area. Plot a graph of area versus concentration and calculate the correlation coefficient. Correlation coefficient should be not

less than 0.9999. The linearity was calculated by measuring different concentration level like 50%, 80%, 90%, 100%, 110%, 120% and 150% for Asenapine Maleate and was shown in Table-5 and Fig. 6-7.

Table 5: Linearity of Asenapine Maleate

Sr. No	Asenapine Maleate peak response as peak area		
	Level (%)	Concentration (µg/mL)	Area response
1	50	25	957053
2	80	40	1539822
3	90	45	1718994
4	100	50	1908453
5	110	55	2093769
6	120	60	2289508
7	150	75	2856071
Correlation coefficient (R)		1.000	
Slope		37900.6407	
Intercept		14222.3210	
Regression coefficient (R ²)		0.999	




Fig 6: Overlay chromatogram of Linearity




Fig 8: Overlay chromatogram of Method precision




Fig 7: Linearity graph of Asenapine Maleate

Ruggedness (Intermediate precision)

Ruggedness of method was performed on a different day and on different make instrument by injecting six replicate of sample preparation. The %RSD of six replicate should not be more than 2% and the overall % RSD should not be more than 2% as shown in Table-7.

Table 7: Results of ruggedness data for asenapine maleate

Preparation No.	Set-I Assay (%w/w)	Set-II Assay (%w/w)
1	98.73	98.61
2	99.31	99.37
3	99.10	97.75
4	98.80	99.20
5	99.13	99.42
6	98.71	98.35
Average	98.96	98.78
SD	0.250	0.665
%RSD	0.25	0.67
Overall average	98.87	
Over all SD	0.488	
Over all % RSD	0.49	
Instrument	Shimadzu LC-2010HT	Waters alliance

Accuracy

The accuracy of the method was determined by analyzing three solutions containing Asenapine Maleate at approximately 50%, 100% and 150% of the working concentration. Each solution was analyzed in triplicate. The % recovery results obtained are shown in Table-8 and Fig. 9. The % recovery at each spike level should be not less than 98% and not more than 102% of the added amount.


Method Precision: To evaluate the method precision, six individual sample solution were prepared and calculate the % of Assay, as shown in Table-6 and Fig. 8. The % RSD for the % Assay of six determination should not be more than 2%.

Table 6: Summary of Results for Precision of The Method for Asenapine Maleate

Injection no.	Assay (%w/w) (Asenapine Maleate)
1	98.73
2	99.31
3	99.10
4	98.80
5	99.13
6	98.71
Average peak area	98.96
SD	0.250
%RSD	0.25

Table 8: Accuracy of Asenapine Maleate

Recovery Level	Asenapine Maleate				
	Amount Added (mg)	Amount Recovered (mg)	% Recovery	Average Recovery (%)	% RSD
50%	25.01	25.2601	101.6	101.4	0.21
	25.04	25.2595	101.5		
	25.11	25.2457	101.2		
100%	50.07	50.2358	101.0	100.8	0.15
	50.09	50.1768	100.8		
	50.16	50.1912	100.7		
150%	75.25	74.7599	100.0	100.1	0.12
	75.09	74.7925	100.2		
	75.20	74.7482	100.0		
Overall % Recovery				100.8	
Overall % RSD				0.61	

**Fig 9:** Overlay chromatogram of Accuracy data

Robustness: Prepared standard solution and test preparation in single as per proposed test method and performed robustness parameter by variation in chromatographic conditions like flow rate ($\pm 10.0\%$), column oven temperature

($\pm 5^\circ\text{C}$), wavelength ($\pm 2\text{nm}$) and mobile phase composition (10% of Organic Phase). Robustness of method is as shown in table 9-10.

Table 9: System suitability for asenapine maleate (Robustness Parameter)

Sr. No.	Robustness Parameter	System Suitability parameter	Observations			Limits
			Test Method	Plus	Minus	
1	Flow	%RSD of six replicate injection	0.01	0.02	0.04	NMT 2
		Tailing Factor	1.04	1.20	1.23	NMT 2
		Theoretical Plates	7227	7202	7968	NLT 2000
2	Wavelength	%RSD of six replicate injection	0.01	0.01	0.03	NMT 2
		Tailing Factor	1.04	1.20	1.20	NMT 2
		Theoretical Plates	7227	7469	7517	NLT 2000
3	Column Oven	%RSD of six replicate injection	0.01	0.11	0.02	NMT 2
		Tailing Factor	1.04	1.23	1.21	NMT 2
		Theoretical Plates	7227	8215	7018	NLT 2000
4	Mobile Phase Composition	%RSD of six replicate injection	0.01	0.03	0.04	NMT 2
		Tailing Factor	1.04	1.21	1.27	NMT 2
		Theoretical Plates	7227	6558	9017	NLT 2000

Table 10: Precision data compilation asenapine maleate (Robustness Parameter)

Robustness Parameter	Set-Robustness	Method precision Data						%RSD
		Set-1	Set-2	Set-3	Set-4	Set-5	Set-6	
Minus Wavelength	99.72	98.73	99.31	99.10	98.80	99.13	98.71	0.37
Plus Wavelength	99.79	98.73	99.31	99.10	98.80	99.13	98.71	0.39
Minus Flow Rate	99.53	98.73	99.31	99.10	98.80	99.13	98.71	0.32
Plus Flow Rate	99.61	98.73	99.31	99.10	98.80	99.13	98.71	0.34
Minus Column Temp.	99.56	98.73	99.31	99.10	98.80	99.13	98.71	0.32
Plus Column Temp.	100.07	98.73	99.31	99.10	98.80	99.13	98.71	0.48
Minus Organic	99.90	98.73	99.31	99.10	98.80	99.13	98.71	0.42
Plus Organic	98.34	98.73	99.31	99.10	98.80	99.13	98.71	0.33

Conclusion

A specific, precise, accurate, less time consuming and simple method was developed for the quantitative estimation of Asenapine Maleate in bulk drug and buccal formulation using RP-HPLC and validated as per ICH guidelines. The result of the analysis by the proposed method is highly reproducible and reliable. Robustness and ruggedness of method leads its application from small college lab to a quality control department of big pharmaceutical organization.

Acknowledgement

The authors are thankful to Sun Pharmaceutical Ltd., Vadodara, Gujarat, India. Who supplied Asenapine Maleate active pharmaceutical ingredient for present study. We are heartily thank full to Vovantis laboratories private limited for providing necessary facilities to carry out this research work.

References

1. <https://pubchem.ncbi.nlm.nih.gov/compound/71311991> (Accessed on June 2018).
2. <https://www.drugbank.ca/salts/DBSALT000010> (Accessed on June 2018).
3. Center for Drug Evaluation and Research, Application Number 22-117, 2007.
4. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine- A novel Pscopharmacologic agent with a unique human receptor signature. *J Psychopharmacology*. 2009; 23:65-73.
5. Halima OA, Aneesh TP, Ghosh R, Thomas NR. Development and validation of UV spectrophotometric method for the estimation of Asenapine Maleate in bulk and pharmaceutical formulation. *Der Pharma Chemica*. 2012; 4(2):644-649.
6. Mrudulesh Y, Ravi sankar P, Devadasu CH, Srinivas Babu P. Development and validation of spectrophotometric method for the quantitative estimation of Asenapine Maleate in bulk drug. *Journal of Chemical and pharmaceutical science*. 2013; 6(4):227-230.
7. Aneesh TP, Rajasekaran A. Stress degradation studies and development and validation of RP-HPLC method for estimation of Asenapine Maleate. *International Journal of Pharmacy and Pharmaceutical science*. 2012; 4(4):448-451.
8. ICH Guidelines, Validation of Analytical Procedures: Text and Methodology, Q2 (R1), 2005.
9. Wilson & Gisvold's: Text book of Organic & Pharmaceutical Chemistry, Lippincott Williams & wilkins publisher, 11th edition, 724-725.
10. Gurudeep RC, Sham KA. Instrumental methods of chemical analysis. Himalaya Publishing house, 2.149-2.182.